【摘要】 目的探讨成人Xp11.2易位/TFE3基因融合相关性肾癌的临床特点和诊治方案。方法结合文献,回顾性分析2009年5月至2015年6月我院收治的8例经病理检查确诊为Xp11.2易位/TFE3基因融合相关性肾癌成人患者的临床资料。结果 8例患者结合组织病理学和免疫组化结果得以确诊,均行手术治疗,3例辅助靶向治疗,术后随访3~69个月,5例无瘤存活,3例复发死亡。结论 Xp11.2易位/TFE3基因融合相关性肾癌是一种罕见的肾癌亚型,成年患者预后欠佳,早期诊断、积极治疗、密切随访能有效改善预后。更多还原

【Abstract】 Objective To explore the clinical features and treatment of renal cell carcinoma associated with Xp11.2translocation/TFE3 gene fusion in adults. Methods Retrospective analysis the clinical data of 8adult renal cell carcinoma associated with Xp11.2translocation/TFE3 gene fusions in our hospital in May 2009 to July 2015. Results 8cases were diagnosed by pathology and immunohistochemistry and treated with operation,3cases with auxiliary targeted therapy.Patients were followed up for 3to 69 months,and 5patients were alive without tumor,and 3patients died from recurrence. Conclusions Renal cell carcinoma associated with Xp11.2translocation/TFE3 gene fusion is a rare subtype with poor prognosis in adult patients.The prognosis could be effectively improved by early diagnosis,active treatment and close follow-up.更多还原